Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06457074 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Finerenone for Patients With Primary Aldosteronism (FAIRY)

StatusCompleted
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Sponsor changed: Qifu Li to Chongqing Medical University Show 7 more changesShow less
    • Primary completion date changed from estimate of Jun 1, 2025 to Apr 20, 2026
    • Trial status changed: Unknown → Completed
    • Eligibility criteria expanded, about 33 words
    • Secondary endpoints: 9 to 12
    • Site details revised
    • Collaborators: 4 to 12
    • Publications: details revised at 15 of 15 entries
  2. Changed Registry marked status Unknown; last known: Recruiting
  3. Trial status: Recruiting to Unknownv4
  4. Re-verified, no change to tracked fieldsv3
  5. Start date: May 30, 2024 to Jun 4, 2024v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Using spironolactone as the control, to assess the efficacy and safety of finerenone in patients with primary aldosteronism(PA).
Trial Details
NCT Number NCT06457074
Lead Sponsor Chongqing Medical University
Collaborators: Affiliated Hospital of Southwest Medical University, First Affiliated Hospital, Sun Yat-Sen University, The People's Hospital of Chuxiong Yi Autonomous Prefecture, First Affiliated Hospital of Kunming Medical University, Shanghai Public Health Clinical Center, Tianjin Medical University General Hospital, The First Affiliated Hospital with Nanjing Medical University, Second Xiangya Hospital of Central South University, WanSheng People's Hospital of ChongQing, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Affiliated Hospital of Nantong University, First Affiliated Hospital of Chongqing Medical University
Conditions
(from sponsor)		 Primary Aldosteronism
Related terms Hyperaldosteronism
Enrollment 306 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov